1
|
Alsyouf M, Nappi L, Nichols C, Daneshmand S. Plasma Micro-RNA 371 Expression in Early-Stage Germ Cell Tumors: Are We Ready to Move Toward Biology-Based Decision Making? J Clin Oncol 2023; 41:2478-2482. [PMID: 36758194 DOI: 10.1200/jco.22.02002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023] Open
Affiliation(s)
- Muhannad Alsyouf
- Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA
| | - Lucia Nappi
- Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Craig Nichols
- Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Siamak Daneshmand
- Department of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA
| |
Collapse
|
2
|
Dieckmann KP, Dumlupinar C, Radtke A, Matthies C, Pichler R, Paffenholz P, Sommer J, Winter A, Zengerling F, Hennig F, Wülfing C, Belge G. Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1. World J Urol 2021; 40:317-326. [PMID: 34775512 PMCID: PMC8921024 DOI: 10.1007/s00345-021-03876-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Accepted: 10/30/2021] [Indexed: 12/27/2022] Open
Abstract
Purpose Lymphovascular invasion (LV1) and presence of > 50% embryonal carcinoma (> 50% EC) represent risk factors for progression in patients with clinical stage 1 (CS1) nonseminomatous (NS) testicular germ cell tumours. As serum levels of microRNA-371a-3p (M371) are capable of detecting small amounts of GCT, we evaluated if LV1 and > 50% EC are associated with M371 levels. Methods M371 serum levels were measured postoperatively in 153 NS CS1 patients and both pre- and postoperatively in 131 patients. We registered the following factors: age, tumour size, LV status, > 50% EC, teratoma in primary, preoperative elevation of classical tumour markers. M371 expression was compared among subgroups. The ability of M371 to predict LV1 was calculated by receiver operating characteristics (ROC) curves. Multiple regression analysis was used to look for associations of M371 levels with other factors. Results Postoperatively elevated M371 levels were found in 29.4% of the patients, but were neither associated with LV status nor with > 50% EC. Likewise, relative decrease of M371 was not associated. ROC analysis of postoperative M371 levels revealed an AUC of 0.5 for the ability to predict LV1 while preoperative M371 had an AUC of 0.732. Multiple regression analysis revealed significant associations of preoperative M371 levels with LV status (p = 0.003), tumour size (p = 0.001), > 50% EC (p = 0.004), and teratoma component (p = 0.045). Conclusion Postoperatively elevated M371 levels are not associated with risk factors for progression in NS CS1 patients. However, the significant association of preoperative M371 expression with LV1 deserves further evaluation.
Collapse
Affiliation(s)
| | - Cansu Dumlupinar
- Faculty of Biology and Chemistry, University Bremen, Leobener Strasse 2/FVG, 28359, Bremen, Germany
| | | | - Cord Matthies
- Department of Urology, Bundeswehrkrankenhaus Hamburg, Hamburg, Germany
| | - Renate Pichler
- Department of Urology, University Hospital Innsbruck, Innsbruck, Austria
| | - Pia Paffenholz
- Department of Urology, University Hospital Cologne, Cologne, Germany
| | - Jörg Sommer
- Department of Urology, St. Franziskus Krankenhaus Lohne, Lohne, Germany
| | - Alexander Winter
- Department of Urology, University Hospital Oldenburg, Oldenburg, Germany
| | | | - Finja Hennig
- Faculty of Biology and Chemistry, University Bremen, Leobener Strasse 2/FVG, 28359, Bremen, Germany
| | | | - Gazanfer Belge
- Faculty of Biology and Chemistry, University Bremen, Leobener Strasse 2/FVG, 28359, Bremen, Germany.
| |
Collapse
|
3
|
Nason GJ, Chung P, Warde P, Huddart R, Albers P, Kollmannsberger C, Booth CM, Hansen AR, Bedard PL, Einhorn L, Nichols C, Rendon RA, Wood LA, Jewett MAS, Hamilton RJ. Controversies in the management of clinical stage 1 testis cancer. Can Urol Assoc J 2020; 14:E537-E542. [PMID: 32569575 DOI: 10.5489/cuaj.6722] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
In November 2018, The Canadian Testis Cancer Workshop was convened. The two-day workshop involved urologists, medical and radiation oncologists, pathologists, radiologists, physician’s assistants, residents and fellows, nurses, patients and patient advocacy groups. One of the goals of the workshop was to discuss the challenging areas of testis cancer care where guidelines may not be specific. The objective was to distill through discussion around cases, expert approach to working through these challenges. Herein we present a summary of discussion from the workshop around controversies in the management of clinical stage 1 (CS1) disease. CS1 represents organ confined non-metastatic testis cancer that represents approximately 70-80% of men at presentation. Regardless of management, CS1 has an excellent prognosis. However, without adjuvant treatment, approximately 30% of CS1 nonseminomatous germ cell tumors (NSGCT) and 15% of CS1 seminoma relapse. The workshop reviewed that while surveillance has become the standard for the majority of patients with CS1 disease there remains debate in the management of patients at high-risk of relapse. The controversy in the management of CS1 testis cancer surrounds the optimal balance between the morbidity of overtreatment and the identification of patients who may derive most benefit from adjuvant treatment. The challenge lies in a shared decision process where discussion of options extends beyond the simple risk of relapse but to include the long-term toxicities of adjuvant treatments and the favorable cancer-specific survival.
Collapse
Affiliation(s)
- Gregory J Nason
- Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - Peter Chung
- Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
| | - Padraig Warde
- Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
| | - Robert Huddart
- The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Peter Albers
- Department of Urology, Heinrich-Heine University, Medical Faculty, Düsseldorf, Germany
| | - Christian Kollmannsberger
- British Columbia Cancer Agency Vancouver Cancer Centre, University of British Columbia, Vancouver, BC, Canada
| | - Christopher M Booth
- Cancer Care and Epidemiology, Cancer Research Institute, Queen's University, Kingston, ON, Canada
| | - Aaron R Hansen
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - Philippe L Bedard
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - Lawrence Einhorn
- Department of Oncology, Indiana University School of Medicine, Indianapolis, IN, United States
| | - Craig Nichols
- Testicular Cancer Multidisciplinary Clinic, Virginia Mason Medical Center, Seattle, WA, United States
| | - Ricardo A Rendon
- Department of Urology, Dalhousie University, Halifax, NS, Canada
| | - Lori A Wood
- Division of Medical Oncology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada
| | - Michael A S Jewett
- Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - Robert J Hamilton
- Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, Toronto, ON, Canada
| |
Collapse
|
4
|
Allard CB, Blute ML. TESTICULAR CANCER. Cancer 2019. [DOI: 10.1002/9781119645214.ch20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
5
|
Dieckmann KP, Anheuser P, Kulejewski M, Gehrckens R, Feyerabend B. Is there still a place for retroperitoneal lymph node dissection in clinical stage 1 nonseminomatous testicular germ-cell tumours? A retrospective clinical study. BMC Urol 2018; 18:95. [PMID: 30367648 PMCID: PMC6204050 DOI: 10.1186/s12894-018-0412-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Accepted: 10/17/2018] [Indexed: 01/22/2023] Open
Abstract
Background Primary retroperitoneal lymph node dissection (RPLND) ultimately lost its role as the standard management of clinical stage (CS) 1 nonseminomatous (NS) testicular germ cell tumours (GCTs) in Europe when the European Germ Cell Cancer Consensus Group released their recommendations in 2008. Current guide-lines recommend surgery only for selected patients but reasons for selection remain rather ill-defined. We evaluated the practice patterns of the management of CS1 patients and looked specifically to the role of RPLND among other standard treatment options. Methods We retrospectively evaluated the treatment modalities of 75 consecutive patients treated for CS1 NS at one centre during 2008–2017. The patients undergoing RPLND were selected for a closer review. Particular reasons for surgery, clinical features of patients, and therapeutic outcome were analyzed using descriptive statistical methods. Results Twelve patients (16%) underwent nerve-sparing RPLND, nine surveillance, 54 had various regimens of adjuvant chemotherapy. Particular reasons for surgery involved illnesses precluding chemotherapy (n = 2), patients´ choice (n = 4), and teratomatous histology of the primary associated with equivocal radiologic findings (n = 6). Five patients had lymph node metastases, two received additional chemotherapy. Antegrade ejaculation was preserved in all cases. One patient had a grade 2 complication that was managed conservatively. All RPLND-patients remained disease-free. Conclusions Primary RPLND is a useful option in distinct CS1 patients, notably those with concurrent health problems precluding chemotherapy, and those with high proportions of teratoma in the primary associated with equivocal radiological findings. Informed patient’s preference represents another acceptable reason for the procedure. RPLND properly suits the needs of well-selected patients with CS1 nonseminoma and deserves consideration upon clinical decision-making.
Collapse
Affiliation(s)
- K-P Dieckmann
- Albertinen-Krankenhaus Hamburg, Klinik für Urologie, Hamburg, Germany. .,Asklepios Klinik Altona, Urologische Abteilung, Hodentumorzentrum Hamburg, Hamburg, Germany. .,Asklepios Klinik Altona, Hodentumorzentrum Hamburg, Paul Ehrlich Strasse 1, 22763, Hamburg, Germany.
| | - P Anheuser
- Albertinen-Krankenhaus Hamburg, Klinik für Urologie, Hamburg, Germany
| | - M Kulejewski
- Albertinen-Krankenhaus Hamburg, Klinik für Urologie, Hamburg, Germany
| | - R Gehrckens
- Albertinen-Krankenhaus Hamburg, Klinik für Diagnostische Radiologie, Hamburg, Germany
| | | |
Collapse
|
6
|
Hu Z, Yu J, Gui G, Chen Y, Huang R, Jiang L, Kwong JSW, Li Y, Zhang L. Cisplatin for testicular germ cell tumors: a rapid review. J Evid Based Med 2016; 9:144-151. [PMID: 27376482 DOI: 10.1111/jebm.12210] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/22/2015] [Accepted: 06/22/2016] [Indexed: 02/05/2023]
Abstract
OBJECTIVE Cisplatin is one of efficacious medicines for TGCT, but is not in 18th WHO EML now. The Union for International Cancer Control recommended cisplatin to the 19th WHO EML for TGCT. To evaluate the effectiveness, safety and cost of cisplatin for TGCT according to the requirements of WHO EML Expert Committee, and to provide the evidence whether cisplatin should be included in WHO EML. METHOD We searched The Cochrane Library, PubMed, EMbase, NHS EED, US National Guideline Clearinghouse (NGC) and WHO guidelines. Guidelines and systematic reviews (SRs) on cisplatin for TGCT were included. Two reviewers selected studies and extracted relevant information independently. Quality of SRs was appraised through AMSTAR. RESULTS Seven guidelines and four SRs were included in this rapid review. Quality of SRs was moderate according to AMSTAR. The results showed that: (a) effectiveness: cisplatin-based chemotherapy significantly improved in response rates and overall survival for more advanced disease (stage II and stage III). Bleomycin, etoposide, and cisplatin (BEP)-one of the most widely used of cisplatin-based chemotherapy regimens should be considered as the standard treatment of good-prognosis patients with survival rates of 90% and as the best option for intermediate- or poor-prognosis patients with survival rates of 75% and 50%, respectively. (b) Safety: nephrotoxicity, ototoxicity and peripheral neuropathy are common adverse effects of cisplatin. (c) Cost: there was no relevant study about cost of cisplatin for TGCT. But the affordability of cispaltin is good for Chinese patients, due to it is in health insurance directory of China. CONCLUSIONS We recommend cisplatin to be listed in 19th WHO EML for TGCT, due to adequate evidence of effectiveness and good affordability.
Collapse
Affiliation(s)
- Zhiqiang Hu
- Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China
- Key Laboratory of Birth Defects and Related Diseases of Women and Children, Chengdu, China
| | - Jiajie Yu
- Chinese evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
| | - Ge Gui
- Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China
- Key Laboratory of Birth Defects and Related Diseases of Women and Children, Chengdu, China
| | - Yuan Chen
- Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China
- Key Laboratory of Birth Defects and Related Diseases of Women and Children, Chengdu, China
| | - Rui Huang
- Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China
- Key Laboratory of Birth Defects and Related Diseases of Women and Children, Chengdu, China
| | - Lucan Jiang
- Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China
- Key Laboratory of Birth Defects and Related Diseases of Women and Children, Chengdu, China
| | - Joey S W Kwong
- Chinese evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
| | - Youping Li
- Chinese evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
| | - Lingli Zhang
- Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China
| |
Collapse
|
7
|
Harada KI, Miyake H, Ogawa T, Inoue TA, Fujisawa M. Oncological Outcomes in Japanese Men Undergoing Orchiectomy for Stage I Testicular Germ Cell Tumor. Curr Urol 2016; 8:84-90. [PMID: 26889123 DOI: 10.1159/000365695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2014] [Accepted: 06/19/2014] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND The objective of this study was to retrospectively review oncological outcomes in patients with stage I testicular germ cell tumor (GCT). PATIENTS AND METHODS This study included 265 consecutive Japanese men undergoing orchiectomy for stage I testicular GCT, and a retrospective review of their records was performed. RESULTS Of these 265 patients, 192 and 73 were pathologically classified with seminoma and nonseminoma, respectively. Prophylactic radiation and chemotherapy were performed in 62 patients with seminoma and 6 with nonseminoma, respectively. Disease recurrence occurred in 12 seminoma patients, of whom 11 had not received prophylactic radiation therapy; however, all 12 achieved a complete response to bleomycin, etoposide and cisplatin therapy. Of the nonseminoma patients, 19 experienced disease recurrence and were then treated with bleomycin, etoposide and cisplatin followed additionally by the surgical resection of residual tumors and salvage chemotherapy in 7 and 4, respectively. There was no cancer-specific death in the 265 patients, and 5-year recurrence-free survival rates in patients with seminoma and nonseminoma were 92.6 and 72.8%, respectively. Furthermore, following factors appeared to be significantly associated with recurrence-free survival in these patients: age, T classification, microvascular invasion and adjuvant therapy for those with seminoma, and microvascular invasion for those with nonseminoma. CONCLUSIONS Despite a generally favorable prognosis in Japanese men with stage I testicular GCT, intensive follow-up or prophylactic therapy should be considered for men with possible risk factors of disease recurrence.
Collapse
Affiliation(s)
- Ken-Ichi Harada
- Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Hideaki Miyake
- Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Takayoshi Ogawa
- Department of Urology, Himeji Red Cross Hospital, Himeji, Japan
| | - Taka-Aki Inoue
- Department of Urology, Hyogo Cancer Center, Akashi, Japan
| | - Masato Fujisawa
- Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
8
|
Daugaard G, Gundgaard MG, Mortensen MS, Agerbæk M, Holm NV, Rørth M, von der Maase H, Christensen IJ, Lauritsen J. Surveillance for Stage I Nonseminoma Testicular Cancer: Outcomes and Long-Term Follow-Up in a Population-Based Cohort. J Clin Oncol 2014; 32:3817-23. [DOI: 10.1200/jco.2013.53.5831] [Citation(s) in RCA: 152] [Impact Index Per Article: 15.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Purpose To describe treatment results in a large cohort with stage I nonseminoma germ cell cancer (NSGCC) treated in a surveillance program. Patients and Methods From January 1, 1984, to December 31, 2007, 1,226 patients with stage I NSGCC, including high-risk patients with vascular invasion, were observed in a surveillance program. Results The relapse rate after orchiectomy alone was 30.6% at 5 years. Presence of vascular invasion together with embryonal carcinoma and rete testis invasion in the testicular primary identified a group with a relapse risk of 50%. Without risk factors, the relapse risk was 12%. Eighty percent of relapses were diagnosed within the first year after orchiectomy. The median time to relapse was 5 months (range, 1 to 308 months). Early relapses were mainly detected by increase in tumor markers, and late relapses were detected by computed tomography scans. Relapses after 5 years were seen in 0.5% of the whole cohort or in 1.6% of relapsing patients. The majority of relapses (94.4%) belonged to the good prognostic group according to the International Germ Cell Cancer Collaborative Group classification. The disease-specific survival at 15 years was 99.1%. Conclusion A surveillance policy for patients with stage I NSGCC is a safe approach associated with an excellent cure rate and an overall low treatment burden despite a high relapse rate in a small group of patients. We recommend surveillance for patients with stage I NSGCC with immediate systemic treatment at relapse. Clearly defined risk factors for relapse are presented if an option of risk-adapted treatment is preferred.
Collapse
Affiliation(s)
- Gedske Daugaard
- Gedske Daugaard, Maria Gry Gundgaard, Mette Saksø Mortensen, Mikael Rørth, Hans von der Maase, Ib Jarle Christensen, and Jakob Lauritsen, Copenhagen University, Rigshospitalet, Copenhagen; Mads Agerbæk, Aarhus University Hospital, Aarhus; and Niels Vilstrup Holm, Odense University Hospital, Odense, Denmark
| | - Maria Gry Gundgaard
- Gedske Daugaard, Maria Gry Gundgaard, Mette Saksø Mortensen, Mikael Rørth, Hans von der Maase, Ib Jarle Christensen, and Jakob Lauritsen, Copenhagen University, Rigshospitalet, Copenhagen; Mads Agerbæk, Aarhus University Hospital, Aarhus; and Niels Vilstrup Holm, Odense University Hospital, Odense, Denmark
| | - Mette Saksø Mortensen
- Gedske Daugaard, Maria Gry Gundgaard, Mette Saksø Mortensen, Mikael Rørth, Hans von der Maase, Ib Jarle Christensen, and Jakob Lauritsen, Copenhagen University, Rigshospitalet, Copenhagen; Mads Agerbæk, Aarhus University Hospital, Aarhus; and Niels Vilstrup Holm, Odense University Hospital, Odense, Denmark
| | - Mads Agerbæk
- Gedske Daugaard, Maria Gry Gundgaard, Mette Saksø Mortensen, Mikael Rørth, Hans von der Maase, Ib Jarle Christensen, and Jakob Lauritsen, Copenhagen University, Rigshospitalet, Copenhagen; Mads Agerbæk, Aarhus University Hospital, Aarhus; and Niels Vilstrup Holm, Odense University Hospital, Odense, Denmark
| | - Niels Vilstrup Holm
- Gedske Daugaard, Maria Gry Gundgaard, Mette Saksø Mortensen, Mikael Rørth, Hans von der Maase, Ib Jarle Christensen, and Jakob Lauritsen, Copenhagen University, Rigshospitalet, Copenhagen; Mads Agerbæk, Aarhus University Hospital, Aarhus; and Niels Vilstrup Holm, Odense University Hospital, Odense, Denmark
| | - Mikael Rørth
- Gedske Daugaard, Maria Gry Gundgaard, Mette Saksø Mortensen, Mikael Rørth, Hans von der Maase, Ib Jarle Christensen, and Jakob Lauritsen, Copenhagen University, Rigshospitalet, Copenhagen; Mads Agerbæk, Aarhus University Hospital, Aarhus; and Niels Vilstrup Holm, Odense University Hospital, Odense, Denmark
| | - Hans von der Maase
- Gedske Daugaard, Maria Gry Gundgaard, Mette Saksø Mortensen, Mikael Rørth, Hans von der Maase, Ib Jarle Christensen, and Jakob Lauritsen, Copenhagen University, Rigshospitalet, Copenhagen; Mads Agerbæk, Aarhus University Hospital, Aarhus; and Niels Vilstrup Holm, Odense University Hospital, Odense, Denmark
| | - Ib Jarle Christensen
- Gedske Daugaard, Maria Gry Gundgaard, Mette Saksø Mortensen, Mikael Rørth, Hans von der Maase, Ib Jarle Christensen, and Jakob Lauritsen, Copenhagen University, Rigshospitalet, Copenhagen; Mads Agerbæk, Aarhus University Hospital, Aarhus; and Niels Vilstrup Holm, Odense University Hospital, Odense, Denmark
| | - Jakob Lauritsen
- Gedske Daugaard, Maria Gry Gundgaard, Mette Saksø Mortensen, Mikael Rørth, Hans von der Maase, Ib Jarle Christensen, and Jakob Lauritsen, Copenhagen University, Rigshospitalet, Copenhagen; Mads Agerbæk, Aarhus University Hospital, Aarhus; and Niels Vilstrup Holm, Odense University Hospital, Odense, Denmark
| |
Collapse
|
9
|
Alami M, Janane A, Abbar M, Ameur A, Ghadouane M. [Testicular yolk sac tumor: a rare entity in adults]. Pan Afr Med J 2014; 18:80. [PMID: 25400847 PMCID: PMC4231242 DOI: 10.11604/pamj.2014.18.80.4270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2014] [Accepted: 05/03/2014] [Indexed: 11/11/2022] Open
Abstract
La tumeur testiculaire du sac vitellin pure est rare chez l'adulte. Son diagnostic est histologique, elle reproduit une structure extra-embryonnaire (le tissue du sinus endodermique). Son traitement est codifié. Le pronostic est moins bon chez l'adulte. Nous en rapportons un cas et nous discutons l'histogénèse, les attitudes thérapeutiques, le suivi et le pronostic chez l'adulte.
Collapse
Affiliation(s)
- Mohammed Alami
- Service d'Urologie de l'Hôpital Militaire Universitaire Mohamed V, Rabat, Maroc
| | - Abdellatif Janane
- Service d'Urologie de l'Hôpital Militaire Universitaire Mohamed V, Rabat, Maroc
| | - Mohamed Abbar
- Service d'Urologie de l'Hôpital Militaire Universitaire Mohamed V, Rabat, Maroc
| | - Ahmed Ameur
- Service d'Urologie de l'Hôpital Militaire Universitaire Mohamed V, Rabat, Maroc
| | - Mohamed Ghadouane
- Service d'Urologie de l'Hôpital Militaire Universitaire Mohamed V, Rabat, Maroc
| |
Collapse
|
10
|
Cunniffe N, Robson J, Mazhar D, Williams M. Clinical Examination Does Not Assist in the Detection of Systemic Relapse of Testicular Germ Cell Tumour. Clin Oncol (R Coll Radiol) 2012; 24:39-42. [DOI: 10.1016/j.clon.2011.06.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2010] [Revised: 05/03/2011] [Accepted: 05/05/2011] [Indexed: 10/18/2022]
|
11
|
Hyams ES, Pierorazio P, Proteek O, Sroka M, Kavoussi LR, Allaf ME. Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumor: A Large Single Institution Experience. J Urol 2012; 187:487-92. [PMID: 22177913 DOI: 10.1016/j.juro.2011.10.035] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2011] [Indexed: 10/14/2022]
Affiliation(s)
- Elias S. Hyams
- The Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland and Smith Urological Institute, Long Island Jewish Hospital (OP, LRK), New Hyde Park, New York
| | - Phillip Pierorazio
- The Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland and Smith Urological Institute, Long Island Jewish Hospital (OP, LRK), New Hyde Park, New York
| | - Ornab Proteek
- The Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland and Smith Urological Institute, Long Island Jewish Hospital (OP, LRK), New Hyde Park, New York
| | - Myrna Sroka
- The Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland and Smith Urological Institute, Long Island Jewish Hospital (OP, LRK), New Hyde Park, New York
| | - Louis R. Kavoussi
- The Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland and Smith Urological Institute, Long Island Jewish Hospital (OP, LRK), New Hyde Park, New York
| | - Mohamad E. Allaf
- The Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland and Smith Urological Institute, Long Island Jewish Hospital (OP, LRK), New Hyde Park, New York
| |
Collapse
|
12
|
Sun M, Abdollah F, Budaüs L, Liberman D, Tian Z, Morgan M, Johal R, Schmitges J, Shariat SF, Montorsi F, Greafen M, Perrotte P, Karakiewicz PI. Trends of Retroperitoneal Lymphadenectomy Use in Patients with Nonseminomatous Germ Cell Tumor of the Testis: A Population-Based Study. Ann Surg Oncol 2011; 18:2997-3004. [PMID: 21509630 DOI: 10.1245/s10434-011-1722-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2010] [Indexed: 11/18/2022]
Affiliation(s)
- Maxine Sun
- Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center (CHUM), Montreal, QC, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Fosså SD, Cvancarova M, Chen L, Allan AL, Oldenburg J, Peterson DR, Travis LB. Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients. J Clin Oncol 2011; 29:963-70. [PMID: 21300926 DOI: 10.1200/jco.2010.32.3204] [Citation(s) in RCA: 91] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE The prognostic significance of age at testicular cancer (TC) diagnosis, socioeconomic status (SES), race, and marital status on TC-specific mortality is not well-characterized. In a cancer that is so curable, it is important to identify any influence that confers an increased risk of TC-specific mortality. PATIENTS AND METHODS Using multivariate cause-specific Cox regression models that accounted for competing risks, hazard ratios (HRs) were calculated for 10-year TC-specific mortality among 27,948 patients with TC reported to the Surveillance, Epidemiology and End Results program (1978 to 2006). Independent predictors were age at diagnosis, SES, race, marital status, extent of disease (EOD), calendar year of diagnosis, radiotherapy, and retroperitoneal lymph node dissection (RPLND). RESULTS Compared with younger patients, diagnostic age 40+ was associated with increased mortality (seminoma, HR, 2.00, P < .001; nonseminoma, HR, 2.09; P < .001; most evident in metastatic disease, HR, 8.62; P < .001; HR, 6.35; P < .001, respectively). Unmarried men had two-to three-fold excess mortality compared to married men (HR, 2.97; P < .001; HR, 1.54; P < .001, respectively). Among nonseminoma patients, decreasing SES (P trend < .001) and nonwhite race (HR, 2.11; P < .001) increased mortality. Diagnosis after 1987 resulted in reduced mortality compared to earlier calendar years (HR, 0.58; P = .001; HR, 0.74; P = .001, respectively). Lack of RPLND was associated with seven-fold increase in death (P < .001). CONCLUSION TC-specific mortality is doubled among US patients diagnosed with seminoma or nonseminoma after age 40, even when initial treatment and EOD are taken into account. Among men with nonseminoma, nonwhite race and lower SES also significantly increase TC-specific mortality. Additional research is needed, enabling the development of interventional strategies and preventive approaches, as applicable.
Collapse
|
14
|
Valadares D, Nery F, Marques F. Twelve Years of Experience in the Management of Testicular Germ Cell Tumors at a Referral Center in Portugal. World J Oncol 2010; 1:187-193. [PMID: 29147205 PMCID: PMC5649796 DOI: 10.4021/wjon245w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/30/2010] [Indexed: 11/21/2022] Open
Abstract
Background Testicular germ cell tumors (TGCT) are generally rare but quite frequent in young males. Guidelines are well established for their management. Methods We present the first report from Portugal on clinical, histological, treatment modalities and outcomes of a population with TGCT. Data was retrospectively analyzed for the 1996 through 2008 period, applying a previous internally validated protocol. Results Seventy nine patients with TGCT were identified, 40.5% had seminomatous and 59.5% nonseminomatous tumors. Incidence rates were higher among males in their twenties and thirties. Pain and swelling testis were the most common symptoms and microlithiasis was detected in 20.3% of patients. Lower stages were more frequent in seminomatous tumors. Orchiectomy was done in all patients and further therapy was performed by guidelines recommendations in 86.1% of them. Hematological toxicity was found in 44.3% of the population studied and free disease survival rates were at 88.6%. Conclusions This retrospective study corroborates the European Western country trends concerning TGCT. Mortality was only seen in nonseminomatous TGCT group. Good risk and lower TGCT stages have no deaths reported. Public health campaigns should be undertaken to guide patients to seek medical advice earlier in the course of the disease.
Collapse
Affiliation(s)
- Diana Valadares
- Department of Internal Medicine, Centro Hospitalar do Porto - Hospital Santo Antonio, Porto, Portugal
| | - Filipe Nery
- Department of Internal Medicine, Centro Hospitalar do Porto - Hospital Santo Antonio, Porto, Portugal
| | - Franklim Marques
- Department of Internal Medicine, Centro Hospitalar do Porto - Hospital Santo Antonio, Porto, Portugal.,Director of Oncology Services, Centro Hospitalar do Porto - Hospital Santo Antonio, Porto, Portugal
| |
Collapse
|
15
|
Wood L, Kollmannsberger C, Jewett M, Chung P, Hotte S, O'Malley M, Sweet J, Anson-Cartwright L, Winquist E, North S, Tyldesley S, Sturgeon J, Gospodarowicz M, Segal R, Cheng T, Venner P, Moore M, Albers P, Huddart R, Nichols C, Warde P. Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J 2010; 4:e19-38. [PMID: 20368885 PMCID: PMC2845668 DOI: 10.5489/cuaj.815] [Citation(s) in RCA: 91] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- Lori Wood
- Division of Medical Oncology, Queen Elizabeth II Health Sciences Centre, Halifax, NS
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|